Study design: Twelve SD rats were divided into four groups with 3 animals/group (Study no. KRICT-2014102701-RPK). Group 1 was dosed with STP0404 at 1 mg/kg by single intravenous administration. Groups 2 to 4 were dosed with STP0404 at 20, 40 and 80 mg/kg, respectively, by single oral administration. The vehicle used for IV study was DMSO: PEG400: Water (5,50:45, v:v:v) and the vehicle used for oral studies was 0.5% (w/v) methylcellulose (MC) in water. Blood samples were collected at 0.0833, 0.25, 0.5, 1, 2, 4, 8, 12 (only for PO groups) and 24 hrs post-dose for Groups 1 to 4. STP0404 concentrations in plasma samples were determined by LC-MS/MS. Preclinical Dog pharmacokinetics study (Study no. 400751-2015020201-DPK): A total of 6 male Beagle dogs were divided into two groups (3 animals/group). Following single STP0404 2 mg/kg oral and intravenous administration to Beagle Dogs, STP0404 concentration was determined in plasma, and pharmacokinetic parameters were calculated. Blood samples were collected at 0.033 (for only IV group), 0.0833, 0.25, 0.5, 1.5, 3, 5, 8, 12 and 24 hrs post dose. The concentrations of STP0404 in plasma were determined by using a LC/MS/MS method.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.